ChemoCentryx Appoints Henry A. McKinnell, Jr. to Board of Directors
October 20 2016 - 8:30AM
ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that effective
October 17, 2016, Henry A. McKinnell, Jr, Ph.D., retired chairman
and chief executive officer of Pfizer Inc., has been appointed to
the Company’s Board of Directors. Dr. McKinnell brings significant
leadership in operations, international alliances, and commercial
experience to ChemoCentryx.
During more than thirty years in the pharmaceutical industry,
Dr. McKinnell held a number of executive positions including
Chairman and Chief Executive Officer of Pfizer Inc. from 2001 until
his retirement in 2006. Dr. McKinnell joined Pfizer in 1971 in
Tokyo, and held positions of increasing responsibility around the
world including president Asia, vice president strategic planning,
chief financial officer and president and chief operating officer.
His recent honors include, among others, the Grand Cordon of the
Order of the Rising Sun, Japan's highest award to those other than
members of the Imperial Family and heads of state; the United
Nations Association of the United States of America's Global
Leadership Award; the Woodrow Wilson Institute Corporate Service
Award; and Stanford University's Graduate School of Business
Arbuckle Award and Excellence in Leadership Award.
“We are honored to have Hank join our Board of Directors. He is
a proven leader, successful in launching and commercializing new
medicines, and building pre-eminent, world-class organizations,”
said Thomas J. Schall, Ph.D., President and Chief Executive
Officer, ChemoCentryx. “Hank’s experience will be invaluable to our
team, especially as we enter the next critical phase of our growth
including initiation of the Phase III program with our lead drug
candidate and subsequently proceeding into the realm of
commercialization. Hank’s leadership and skills in our industry, as
well as his contributions to other areas of human welfare, are
internationally recognized. We look forward to his exceptional
contributions to our enterprise.”
“My deep commitment to developing therapies that advance the
practice of medicine and ultimately make patients’ lives better
makes joining the ChemoCentryx Board a natural fit,” said Dr.
McKinnell. “I look forward to working with the other board members
and the ChemoCentryx management team to accomplish their goal of
developing innovative therapeutics for orphan and rare diseases and
to improve human health.”
Dr. McKinnell currently serves as Chairman of Moody’s
corporation. He also serves as a director of View Ray, Inc. and the
Chairman Emeritus of the Connecticut Science Center. He has served
as a Director of the Trilateral Commission and the Business
Council, and Chairman of the Stanford University Graduate School of
Business Advisory Council, Chairman Emeritus of the Business-Higher
Education Forum, a Fellow of the New York Academy of Medicine, and
a member of the Boards of Trustees of the New York City Public
Library, the New York City Police Foundation and the Economic Club
of New York. He served as the Chairman of the Accordia Global
Health Foundation and also served as a Senior Advisor to Toyota
Motor Corporation's International Advisory Board and the Thomas H.
Lee Private Equity Partnership. He is a Director of the Medal of
Honor Foundation, the Royal Shakespeare Company of America and a
life trustee of the Japan Society. He is the Chairman Emeritus
of the Pharmaceutical Research and Manufacturers of America
(PhRMA), the Food and Drug Law Institute and the Medical Device
Manufacturers Association. He has served as a director of more than
12 public companies over twenty years.
Dr. McKinnell holds a bachelor’s degree in business from the
University of British Columbia and an M.B.A. and Ph.D. from
Stanford University Graduate School of Business. Under the current
appointment, Dr. McKinnell will serve as a Class I director until
the 2018 annual stockholder’s meeting.
About ChemoCentryx
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company
focused on discovering, developing and commercializing
orally-administered therapeutics that target the chemokine and
chemoattractant systems in order to treat autoimmune diseases,
inflammatory disorders and cancer. The chemokine system is a
biological network that regulates inflammation via a collection of
secreted chemokine molecules, or ligands, and their specific cell
surface receptors. Based on its proprietary drug discovery and drug
development platform, ChemoCentryx has generated multiple clinical
and preclinical-stage programs, each targeting distinct chemokine
and chemoattractant receptors with different small molecule
compounds. CCX168 (Avacopan), a C5aR inhibitor, has successfully
completed Phase II development for the treatment of anti-neutrophil
cytoplasmic auto-antibody-associated vasculitis (AAV). CCX168
appears to be safe, well tolerated and successful in allowing
reduction and elimination of high-dose steroids, part of standard
of care for AAV patients, without compromising efficacy or safety
in clinical studies to date. CCX168 is also in Phase II studies for
the treatment of atypical hemolytic uremic syndrome (aHUS) and
immunoglobulin A nephropathy, or IgA nephropathy (IgAN).
ChemoCentryx has licensed exclusive rights to Vifor Pharma to
commercialize CCX168 in Europe and certain other markets outside of
the U.S. and most of Asia. CCX872, a CCR2 inhibitor, successfully
completed Phase I development and is in development for the
treatment of non-resectable pancreatic cancer. CCX140, a distinct
CCR2 inhibitor, successfully completed a Phase II clinical trial
where it was shown to be safe and well tolerated while
demonstrating statistically significant improvement in albuminuria
in patients with diabetic nephropathy. Other clinical programs
include CCX507, a next generation CCR9 inhibitor, which has
successfully completed Phase I development, vercirnon (also known
as Traficet-EN or CCX282) a specific CCR9 inhibitor for the
treatment of inflammatory bowel disease, and CCX354, a CCR1
inhibitor which successfully completed a Phase II clinical trial
for the treatment of rheumatoid arthritis. ChemoCentryx also has
several programs in advanced preclinical development.
Forward-Looking Statements
ChemoCentryx cautions that statements included in this press
release that are not a description of historical facts are
forward-looking statements. Words such as "may," "could," "will,"
"would," "should," "expect," "plan," "anticipate," "believe,"
"estimate," "intend," "predict," "seek," "contemplate,"
"potential," "continue" or "project" or the negative of these terms
or other comparable terminology are intended to identify
forward-looking statements. These statements include the Company's
statements regarding timing of initiation of clinical trials. The
inclusion of forward-looking statements should not be regarded as a
representation by ChemoCentryx that any of its plans will be
achieved. Actual results may differ from those set forth in this
release due to the risks and uncertainties inherent in the
ChemoCentryx business and other risks described in the Company's
filings with the Securities and Exchange Commission ("SEC").
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and ChemoCentryx undertakes no obligation to revise or update this
news release to reflect events or circumstances after the date
hereof. Further information regarding these and other risks is
included under the heading "Risk Factors" in ChemoCentryx's
periodic reports filed with the SEC, including ChemoCentryx's
Annual Report on Form 10-K filed with the SEC March 14, 2016 and
its other reports which are available from the SEC's website
(www.sec.gov) and on ChemoCentryx's website (www.chemocentryx.com)
under the heading "Investors." All forward-looking statements are
qualified in their entirety by this cautionary statement. This
caution is made under the safe harbor provisions of Section 21E of
the Private Securities Litigation Reform Act of 1995.CCXI-G
Contacts:
Susan M. Kanaya
Senior Vice President, Finance and
Chief Financial Officer
investor@chemocentryx.com
Media:
Denise Powell
denise@redhousecomms.com
510.703.9491
Investors:
Steve Klass, Burns McClellan
212.213.0006
sklass@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Apr 2023 to Apr 2024